DuChemBio is investing 34.3 billion Korean won to build South Korea’s first contract development and manufacturing organization (CDMO), a drug-development and production partner, dedicated to radiopharmaceuticals (RPT). The Jeongeup project will include a specialized factory and R&D center, with operations targeted for the second half of 2029 and annual capacity of about 1,000 batches. The company aims to supply South Korea, Japan, China and Taiwan, initially positioning itself as a second vendor for global pharmaceutical companies developing radioisotope ligand therapies (RLT), cancer treatments that deliver radiation through targeted molecules. DuChemBio is discussing CDMO work with three global pharmaceutical companies. The global RLT market is projected to expand from $4.23 billion this year to $29.54 billion by 2034, although recent clinical setbacks at Novartis and Eli Lilly underscore the sector’s risks. DuChemBio will invest in stages, adding radioactive-isotope and active pharmaceutical ingredient production to the site. It expects to break even in 2031 and generate more than 20 billion Korean won in factory sales by 2033. The company is also reviewing RLT candidates targeting TROP2 and FAP, while its diagnostic radiopharmaceutical business remains the main source of cash flow.